Richard Kefford
Broad Institute(US)The University of Sydney(AU)Garvan Institute of Medical Research(AU)UNSW Sydney(AU)Melanoma Institute Australia(AU)Westmead Institute for Medical Research(AU)Macquarie University(AU)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cancer Genomics and Diagnostics
Most-Cited Works
- → Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma(2013)3,383 cited
- → Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations(2012)2,783 cited
- → Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib(2012)2,141 cited
- → Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial(2014)1,753 cited
- → Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma(2017)1,459 cited
- → Whole-genome landscapes of major melanoma subtypes(2017)1,452 cited